US3856942A - Appetite control composition - Google Patents
Appetite control composition Download PDFInfo
- Publication number
- US3856942A US3856942A US00359056A US35905673A US3856942A US 3856942 A US3856942 A US 3856942A US 00359056 A US00359056 A US 00359056A US 35905673 A US35905673 A US 35905673A US 3856942 A US3856942 A US 3856942A
- Authority
- US
- United States
- Prior art keywords
- accordance
- control composition
- appetite control
- appetite
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 235000021407 appetite control Nutrition 0.000 title claims abstract description 73
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 24
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 16
- 229960001948 caffeine Drugs 0.000 claims abstract description 14
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 13
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 229960005274 benzocaine Drugs 0.000 claims abstract description 10
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 10
- 239000000796 flavoring agent Substances 0.000 claims abstract description 9
- 239000005720 sucrose Substances 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 23
- 235000009508 confectionery Nutrition 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 19
- 235000013343 vitamin Nutrition 0.000 claims description 19
- 239000011782 vitamin Substances 0.000 claims description 19
- 229930003231 vitamin Natural products 0.000 claims description 19
- 229930013930 alkaloid Natural products 0.000 claims description 14
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 12
- 229960004793 sucrose Drugs 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 9
- 235000019789 appetite Nutrition 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 9
- 235000020357 syrup Nutrition 0.000 claims description 9
- 239000006188 syrup Substances 0.000 claims description 9
- 230000003444 anaesthetic effect Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- VWZAGCZUPZKTET-UHFFFAOYSA-N 3-(dibutylamino)propyl 4-aminobenzoate;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1.CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 VWZAGCZUPZKTET-UHFFFAOYSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004598 butacaine sulfate Drugs 0.000 claims description 3
- WYNURVZXDYZDKR-UHFFFAOYSA-N butylamino benzoate Chemical compound CCCCNOC(=O)C1=CC=CC=C1 WYNURVZXDYZDKR-UHFFFAOYSA-N 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 230000005923 long-lasting effect Effects 0.000 claims description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 3
- 125000001302 tertiary amino group Chemical group 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 abstract description 6
- 235000019640 taste Nutrition 0.000 abstract description 4
- 239000003607 modifier Substances 0.000 abstract description 2
- 230000000737 periodic effect Effects 0.000 abstract description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract description 2
- 230000004580 weight loss Effects 0.000 description 19
- 235000013361 beverage Nutrition 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000037213 diet Effects 0.000 description 11
- 206010033307 Overweight Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 7
- 235000005686 eating Nutrition 0.000 description 6
- 230000007937 eating Effects 0.000 description 6
- 235000003642 hunger Nutrition 0.000 description 6
- 238000007086 side reaction Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000013585 weight reducing agent Substances 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 235000001916 dieting Nutrition 0.000 description 3
- 230000037228 dieting effect Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 229960004567 aminohippuric acid Drugs 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- -1 aromatic alcohols Chemical class 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229940052295 esters of aminobenzoic acid for local anesthesia Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000008296 Prunus serotina Species 0.000 description 1
- 235000014441 Prunus serotina Nutrition 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000020863 crash diet Nutrition 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 229940099242 dexedrine Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
Definitions
- the drug type of regime relies upon the administration of some drug to reduce the appetite, and thus reduce the caloric intake.
- Amphetamines are widely used for this purpose.
- many people cannot continue to use amphetamines for the time required to lose significant amounts of weight, because of severe side reactions.
- amphetamines cannot continue to use amphetamines for the time required to lose significant amounts of weight, because of severe side reactions.
- weight losses are not maintained.
- Side reactions are also reported for other appetite suppressant drugs.
- the leading proprietary appetite suppressant is essentially caramel candy sold under the trademark AYDS.
- an appetite control composition based on a carbohydrate such as sucrose and/or glucose to obtain the effect of carbohydrate on hunger, as noted by Mayer and Van ltallie, in combination with a nontoxic local anesthetic such as an ester of p-aminobenzoic acid, an alkaloid stimulant such as caffeine, and nutrients if desired to control the appetite and supplement nutrient intake.
- a nontoxic local anesthetic such as an ester of p-aminobenzoic acid
- an alkaloid stimulant such as caffeine
- composition is normally prepared in dosage unit form, in which the proportions of the essential ingredients are selected for the desired effect.
- dosage unit forms can be within the range from about 1 to about 12 g. in weight, per unit.
- Any carbohydrate can be used. Good results have been obtained with sucrose, glucose (dextrose), maltose, fructose. These are conveniently used in naturallyoccurring forms such as corn syrup, cane sugar, and beet sugar. A mixture of sugars such as glucose and sucrose may be advantageously used because the mixture produces an ideal plastic mass.
- the purpose of the carbohydrate is to elevate blood sugar level to a high level, preferably a high-normal level, and consequently the amount of carbohydrate per unit dose is sufficient to maintain blood sugar at this level.
- the amount is within the range from about 1000 to about 12,000 parts by weight, preferably from about 2000 to about 3000 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
- a local anesthetic when placed on the tongue reduces sensation safely and effectively but temporarily on the epithelial end organs in the papillae on the surface of the tongue, the socalled taste buds. Consequently, the effect in the appetite control composition is to reduce the craving of the consumer for food and beverages.
- the amount of local anesthetic is within the range from about 3 to about 20 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
- each dosage unit form of the composition of the invention should contain an amount within the range from about 3 to about 10 mg of anesthetic.
- An amount less than 3 mg may be ineffective in one dosage unit, requiring two or more dosage units for the desired effect.
- An amount in excess of 10 mg may be undesirable if the consumer ingests a large number of dosage units per day, but of course if the number of dosage units ingested is reduced, even this amount can be used.
- the maximum imposed for optimum effect is approximately 5 mg per dosage unit, and when this amount is used, the average number of dosage units per day is from 10 to 20.
- the topical anesthetic can be any local anesthetic which is sparingly soluble in water and therefore too slowly absorbed to be toxic.
- the lower alkyl esters of para-amino benzoic acid that lack a secondary or tertiary amino group are one class, of which benzocaine (ethyl aminobenzoate), butyl aminobenzoate, butacaine sulfate, and orthoform are exemplary.
- benzocaine ethyl aminobenzoate
- butyl aminobenzoate butacaine sulfate
- orthoform are exemplary.
- aromatic alcohols such as benzyl alcohol and saligenin
- certain alkyl halides such as chloroform, and quinine.
- the alkaloid stimulant is caffeine or a caffeinerelated alkaloid, such as theobromine.
- Caffeine is added to modify the flavor of the composition. It also tends to reduce the sweet taste of the composition. At the same time, it also imparts the well-known stimulating effect, relieving fatigue, and thereby helping to suppress the desire of the consumer to eat, since fatigue frequently stimulates hunger and eating.
- the amount of caffeine is within the range from about to about 80 parts by weight, preferably from about 30 to about 40 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
- At least about 25 mg per dosage unit should be used.
- the maximum unit amount is imposed according to the number of dosage units ingested daily. At a lower level per dosage unit the product may be taken somewhat more freely than if at a higher level.
- vitamins can be added to the composition, but these are not essential, and can be omitted.
- the vitamins can include any one or several vitamins, according to the diet that is prescribed. Vitamins A, B complex, C, D and E can be added, and the amounts are selected to provide a useful vitamin supplementation to the diet.
- the vitamin content may accordingly vary widely, within recognized limits, and is in no way critical.
- the amount of vitamins can vary from a fraction of USRDA to several times the USRDA, preferably from about 25% to about 100% of USRDA. USRDA is the United States Recommended Dietary Allowance as established by the Food and Drug Administration.
- the physical form of the composition can be either a liquid or a solid, as desired.
- the dosage unit should be long-lasting in the mouth.
- the consumer can slowly dissolve a single dosage unit for quite some time, if it dissolves very slowly in the mouth, and this automatically reduces the number of dosage units taken per day.
- the composition preferably is in a slowly-dissolving form such as hard candy, or compressed tablets.
- the composition can take a number of forms, such as gum drops, soft candy of other types, such as chocolate bars and drops, or cotton candy, liquid solutions such as beverages, and gelled solutions such as gelatin desserts.
- flavoring components are compatible with the essential ingredients of the composition, and if desired can be used in the usual manner. Both artificial and natural flavorings can be used, such as cherry,
- Niacinamide also adds a bitter flavor that reduces sweetness.
- Gentian is another bitter flavoring that can be used.
- Caffeine also adds a bitter taste.
- the amount of flavoring if used will depend upon the taste per unit dose, and will normally be within the range from about 0 to about 60 parts, preferably from about 20 to about 30 parts, measured in milligrams for a normal size dosage unit. Similar amounts can be used of the coloring agents.
- the candy compositions of the invention can be prepared by the following procedure:
- An aqueous carbohydrate solution is prepared by adding water to the carbohydrate, or a natural syrup such as corn syrup or cane sugar syrup can be used.
- the syrup is then heated, preferably under vacuum, to a cooking temperature, usually 295F, although either a higher or lower temperature can be used. Heating is continued until the syrup has been reduced to a viscous mass of the desired water content.
- the concentrated sugar syrup is then transferred to a suitable blender or mixing slab.
- a uniform blend of alkaloid such as caffeine and anesthetic such as benzocaine is added, and blended thoroughly.
- a suitable blending temperature of the plastic mass is between about 240 and about 275F. Next is added the vitamin premix, and flavors and colors, as desired.
- the plastic mass can then be rolled and formed into discs, using ordinary hard candy compression machines, and allowed to harden at a reduced temperature, such as room temperature.
- EXAMPLE 1 An active ingredient premix is prepared by mixing 630 grams of anhydrous caffeine, U.S.P. with 90 grams of benzocaine, N.F.
- a vitamin blend is formed containing all essential vitamins for inclusion in the finished product.
- the flavor is a wild cherry flavor, manufactured for use in high boiled confections.
- the coloring to be used is FD and C Red, Number 40, which is used in a 10% solution for incorporation in high boiled confections.
- a candy base is prepared by the mixing of ll5.7 pounds of 67% liquid sucrose and 51.7 pounds of high maltose corn syrup. This mixture is then heated to a temperature of 235 to 245 F in a precooker. After attaining the temperature, the mixture is pumped to the vacuum cooker where the temperature is raised to 250 to 270 F under 25 30 inches of vacuum.
- This cooking removes water from the mass, so that the moisture level of the mass upon completion of cooking will be between 0.5 and 1%, and the total final weight of the mass will be about 1 19 pounds of sucrose and high maltose corn syrup solids.
- the cooked mass is then placed in the premixer, where the premixed active ingredients are added.
- the first ingredient to be added is the caffeine and benzocaine premix.
- the next ingredients added are the vitamin premix, color, and flavor.
- the mass is transferred to the mixer cooling table. The mass is worked on this table automatically for a period of 4 to 6 minutes. During this period the mass will obtain a plastic consistency and the temperature will be lowered to between 170 and 190F. The mass is completely homogeneous.
- the mass is then placed into forming equipment and run into discs or tablets that weigh three grams apiece.
- the discs or tablets are then placed on a cooling belt where the temperature is brought from 170F to 80- 90F in a period of 6 minutes.
- the finished candy product is then packaged for shipment.
- EXAMPLE 2 The following is the formulation of a tablet, per tablet unit:
- Amount Ingredient (mg) Caffeine 35 Benzocaine 5 Vitamin mixture l5 Flavoring 3O Dextrose, hydrous 2893 (compressible grade) Magnesium stearate 22 This mix can be compressed and tabletted using conventional tabletting equipment.
- CLINICAL TEST Three hundred and eight obese subjects each at least pounds overweight were then separated into five paired groups, and subjected to a clinical test. Five paired groups of males and females were used in the test, each with a different regime.
- Group I was assigned the amphetamine regime.
- Group ll was assigned the AYDS regime.
- Group II was assigned the willpower regime, with a 35 bling, and cheating between meals, except for the product, and that they could use the product before meals or between meals whenever they had the desire to eat. They were further instructed to do no crash dieting, but merely to cut down on the sizes of their three meals. They were also allowed to drink alcoholic beverages.
- the control product used was the product containing glucose and flavoring only. Supplies of all products were given to the patients on a weekly basis, to ensure their return to the clinic. Prescriptions for the amphetamines were issued weekly, as well.
- Constipation was a fairly frequent side effect, especially among subjects on the OTC suppressant Group ll regime; diarrhea, bloating, excessive gas, nausea and headache were also reported as side reactions caused by the OTC suppressant. Many subjects also complained that the suppressant (carmel candy) was uncomfortable in the mouth, causing dentures, caps and fillings to loosen or to fall out. Dryness of the mouth on occasion was reported by some subjects of Groups W and V. One subject said that the control product (hard candy) caused canker; one subject of Group V complained of insomnia, and one reported nausea.
- the Table shows that the subjects of Group V on the appetite control composition of the invention lost significantly greater amounts of weight than those on any of the other four regimes, and they were continuing to lose an average of 2.2 lbs per week at the end of the fifth month of the test. Patients on the other four regimes during the protracted study continued to demonstrate unsatisfactory results, especially with regard to the number of dropouts.
- the effect of the appetite control composition of the invention as an oral pacifier is considered to be a significant factor in aiding patients on this composition to lose more weight in larger numbers in less time than any of those on the other weight reduction regimes.
- a review of the literature over a 30 year period has shown that with the exception of Feinstein, Dole and Schwartz, The use of a formula diet for weight reduction of obese out-patients, Ann. Intern Med. 48 330-343, (1959), no author has published even a 20 lb weight loss in more than 29% of his patients. The percent of patients losing 40 lbs is far smaller.
- the results of this regime are quite remarkable, as compared to previously reported weight reduction regimes.
- the literature does not show a single successful long-term study using a diet regimen by itself or in combination with drugs, psychologic treatment, or exercise.
- a weight maintenance program was also undertaken for test purposes with those patients participating who had attained their normal or desired weight, in order to ascertain whether this weight was maintained. Histories of maintenance of weight loss show even less success than histories of weight reduction (Fellows Am J M Sc 181 301-312, 1931 Mc Cann and Trulsonl Am DietetA 31 1108-1 110 (1955);Osserman and Dolger Ann Intern Med 34 72-79, (1951); Dole, Schwartz and Thaysen Am J Clin Nutr 2 381-390, (1954) The majority of patients regain all previous weight loss or even exceed previous weight losses. This is especially true of patients on amphetamines, and those attending diet clinics.
- the entire population on the weight maintenance program (13 patients) had been on Group V, the appetite control regime.
- the subjects maintained their normal weight with the appetite control composition of the invention without fluctuating more than 1 or 2 pounds, plus or minus. When a pound or two was gained, they were trained to eliminate the gain the next week by adequate dieting.
- An appetite control composition for oral administration to a human subject to aid him in controlling his weight comprising, in combination, a carbohydrate in an amount to obtain the effect ofcarbohydrate on hunger, and a nontoxic local anesthetic and an alkaloid stimulant in amounts to control the appetite.
- composition in accordance with claim 1, in which the vitamins are selected from the group consisting of Vitamins A, B complex, C, D and E and mixtures thereof.
- carbohydrate is selected from the group consisting of sucrose, glucose, maltose, fructose and dextrose and mixtures thereof.
- composition in accordance with claim 1, in which the carbohydrate is selected from the group consisting of corn syrup, cane sugar, and beet sugar.
- a process for controlling weight of patients which comprises administering orally a composition in accordance with claim 1 and limiting the intake of foods by control of appetite therewith.
Abstract
An appetite control composition is provided, comprised of a flavor or taste modifier and safe mild stimulant such as caffeine, a local anesthetic such as benzocaine or benzyl alcohol, and a carbohydrate base such as sucrose or glucose or a combination thereof. A process for reducing weight is also provided, which includes the periodic administration of this appetite control composition.
Description
nited States Patent [191 urphy Dec. 24, 1974 APPE'llllTE CONTROL COMPOSITION [76] Inventor: Paul L. Murphy, 831 Massachusetts Ave., Cambridge, Mass. 02139 [22] Filed: May 10, 1973 [21] Appl. No.: 359,056
[52] US. Cl. 424/180 [51] Int. Cl. A01n 9/00, AOln 9/28 [58] Field of Search 424/180 [56] References Cited UNITED STATES PATENTS 2,714,083 7/1955 Ferguson, Jr. 167/55 2,935,447 5/1960 Miller et al. 424/180 Primary Examiner-Elbert L. Roberts [5 7] ABSTRACT An appetite control composition is provided, comprised of a flavor or taste modifier and safe mild stimulant such as caffeine, a local anesthetic such as benzocaine or benzyl alcohol, and a carbohydrate base such as sucrose or glucose or a combination thereof. A process for reducing weight is also provided, which includes the periodic administration of this appetite control composition.
28 Claims, N0 Drawings APPETITE CONTROL COMPOSITION Large numbers of people are obese simply because they eat too much. Their overweight is not necessarily the result of eating large meals. It may arise from skipping meals, such as breakfast, but constantly snacking, nibbling or cheating" between meals, or when tired, depressed or bored. Many people will consume large quantities of food and beverages while watching television, or participating in some other passive activity. Their overeating is not necessarily a result of their feeling hungry, but rather a result of their wanting to have something in their mouth. While there are some people who are overweight because of glandular imbalance, endocrine conditions, disease, or other metabolic disorders, it appears that a major proportion of overweight people are overweight because of overeating.
Overweight people who fall in this category are particularly difficult to treat so that they will actually lose weight. A variety of treatments have been proposed, based on restricted diets, plus something added to be sure the patient keeps to the prescribed diet. This something is usually either willpower, or a drug, neither of which is fully satisfactory.
People on a willpower regime may lose weight while on the regime, but as soon as the regime is ended they quickly regain weight, mostly because their longestablished habits of eating and drinking are so in grained that they lack the sustained willpower needed to accept radical changes in these habits except for brief periods of time, such as while they are on the regime. Moreover, in many cases people on a willpower regime are subjected to a crash diet, which may be too restrictive, and whose prolonged use could result in nutritional deficiencies, resulting in a quick return to normal habits when the diet is ended.
The drug type of regime relies upon the administration of some drug to reduce the appetite, and thus reduce the caloric intake. Amphetamines are widely used for this purpose. However, many people cannot continue to use amphetamines for the time required to lose significant amounts of weight, because of severe side reactions. Moreover, it frequently happens that even upon protracted treatment with this drug, weight losses are not maintained. Side reactions are also reported for other appetite suppressant drugs. The leading proprietary appetite suppressant is essentially caramel candy sold under the trademark AYDS.
Mayer OVERWEIGHT: Causes, Cost, and Control, Prentice-Hall, Inc. (1968), page 18, has pointed out that lowering blood glucose levels through injections of insulin leads to gastric contractions and hunger. He postulated that there are in the hypothalmus receptors with a special affinity for glucose, which are activated by this blood component in the measure that they utilize it. Mayer with Van ltallie have verified this theory by demonstrating in man a correlation between utilization of glucose by the body and the state of hunger or satiety. Gastric hunger contractions appear when glucose utilization is low. When the satiety centers are destroyed, glucagon no longer inhibits the stomach contractions of a hungry animal, from which Mayer and Van ltallie concluded that the satiety center did control gastric motility.
In accordance with the invention, an appetite control composition is provided, based on a carbohydrate such as sucrose and/or glucose to obtain the effect of carbohydrate on hunger, as noted by Mayer and Van ltallie, in combination with a nontoxic local anesthetic such as an ester of p-aminobenzoic acid, an alkaloid stimulant such as caffeine, and nutrients if desired to control the appetite and supplement nutrient intake. These ingredients, which are the essential ingredients, can be combined in any suitable form for oral administration, so that the composition is readily ingested by a person desiring to control his or her weight. Because of the carbohydrate content, a candy or sweet is a practical form of composition, but the composition can be in any solid or liquid form, as desired. Additional ingredients can be added, including coloring agents and flavoring agents, to render the composition more palatable, and more attractive to the eye.
The composition is normally prepared in dosage unit form, in which the proportions of the essential ingredients are selected for the desired effect. These dosage unit forms can be within the range from about 1 to about 12 g. in weight, per unit.
Any carbohydrate can be used. Good results have been obtained with sucrose, glucose (dextrose), maltose, fructose. These are conveniently used in naturallyoccurring forms such as corn syrup, cane sugar, and beet sugar. A mixture of sugars such as glucose and sucrose may be advantageously used because the mixture produces an ideal plastic mass.
The purpose of the carbohydrate is to elevate blood sugar level to a high level, preferably a high-normal level, and consequently the amount of carbohydrate per unit dose is sufficient to maintain blood sugar at this level. The amount is within the range from about 1000 to about 12,000 parts by weight, preferably from about 2000 to about 3000 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
A local anesthetic when placed on the tongue reduces sensation safely and effectively but temporarily on the epithelial end organs in the papillae on the surface of the tongue, the socalled taste buds. Consequently, the effect in the appetite control composition is to reduce the craving of the consumer for food and beverages.
The amount of local anesthetic is within the range from about 3 to about 20 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
To obtain an immediate effect to 30 minutes, each dosage unit form of the composition of the invention should contain an amount within the range from about 3 to about 10 mg of anesthetic. An amount less than 3 mg may be ineffective in one dosage unit, requiring two or more dosage units for the desired effect. An amount in excess of 10 mg may be undesirable if the consumer ingests a large number of dosage units per day, but of course if the number of dosage units ingested is reduced, even this amount can be used. The maximum imposed for optimum effect is approximately 5 mg per dosage unit, and when this amount is used, the average number of dosage units per day is from 10 to 20.
The topical anesthetic can be any local anesthetic which is sparingly soluble in water and therefore too slowly absorbed to be toxic. The lower alkyl esters of para-amino benzoic acid that lack a secondary or tertiary amino group are one class, of which benzocaine (ethyl aminobenzoate), butyl aminobenzoate, butacaine sulfate, and orthoform are exemplary. Also useful are aromatic alcohols such as benzyl alcohol and saligenin, certain alkyl halides such as chloroform, and quinine.
Lower alkyl esters of aminobenzoic acid hydrolyze in the stomach to yield aminobenzoic acid and the corresponding alkyl alcohol, which are both water-soluble, and are excreted by the kidneys, specifically as glycine, to form aminohippuric acid, and both the alcohol and aminohippuric acid are excreted in the urine. This mechanism is a specific detoxifying reaction for these esters.
The alkaloid stimulant is caffeine or a caffeinerelated alkaloid, such as theobromine. Caffeine is added to modify the flavor of the composition. It also tends to reduce the sweet taste of the composition. At the same time, it also imparts the well-known stimulating effect, relieving fatigue, and thereby helping to suppress the desire of the consumer to eat, since fatigue frequently stimulates hunger and eating.
The amount of caffeine is within the range from about to about 80 parts by weight, preferably from about 30 to about 40 parts by weight. For a normal size dosage unit, these parts are taken in milligrams.
In order to obtain the effect of caffeine on palatability, at least about 25 mg per dosage unit should be used. The maximum unit amount is imposed according to the number of dosage units ingested daily. At a lower level per dosage unit the product may be taken somewhat more freely than if at a higher level.
It is known that caffeine forms a stabilizing complex with esters of aminobenzoic acid (Higuchi and Lachman, J. Am. Pharm. Assoc. XLIV 52l-6 [1955]) which is resistant to hydrolysis by water. This effect can be advantageous in the compositions of the invention, and therefore such combinations are preferred.
In order to supplement a restricted daily caloric intake, nutrients such as vitamins can be added to the composition, but these are not essential, and can be omitted. The vitamins can include any one or several vitamins, according to the diet that is prescribed. Vitamins A, B complex, C, D and E can be added, and the amounts are selected to provide a useful vitamin supplementation to the diet. The vitamin content may accordingly vary widely, within recognized limits, and is in no way critical. Thus, the amount of vitamins can vary from a fraction of USRDA to several times the USRDA, preferably from about 25% to about 100% of USRDA. USRDA is the United States Recommended Dietary Allowance as established by the Food and Drug Administration.
The physical form of the composition can be either a liquid or a solid, as desired. For maximum effect on appetite control per dosage unit, however, the dosage unit should be long-lasting in the mouth. Thus, the consumer can slowly dissolve a single dosage unit for quite some time, if it dissolves very slowly in the mouth, and this automatically reduces the number of dosage units taken per day. For this reason, the composition preferably is in a slowly-dissolving form such as hard candy, or compressed tablets.
lf slow dissolution is not desired, the composition can take a number of forms, such as gum drops, soft candy of other types, such as chocolate bars and drops, or cotton candy, liquid solutions such as beverages, and gelled solutions such as gelatin desserts.
The usual flavoring components are compatible with the essential ingredients of the composition, and if desired can be used in the usual manner. Both artificial and natural flavorings can be used, such as cherry,
strawberry, orange, lemon, lime, raspberry, blackberry, currant, coffee, peppermint, apple, apricot, peach and grape. Artifical colorings can also be added, such as red, orange, green, yellow, or brown, to improve the appearance of the composition.
Quinine and its salts, if added, add a bitter flavor which reduces sweetness. Niacinamide also adds a bitter flavor that reduces sweetness. Gentian is another bitter flavoring that can be used. Caffeine also adds a bitter taste.
The amount of flavoring if used will depend upon the taste per unit dose, and will normally be within the range from about 0 to about 60 parts, preferably from about 20 to about 30 parts, measured in milligrams for a normal size dosage unit. Similar amounts can be used of the coloring agents.
The candy compositions of the invention can be prepared by the following procedure:
An aqueous carbohydrate solution is prepared by adding water to the carbohydrate, or a natural syrup such as corn syrup or cane sugar syrup can be used. The syrup is then heated, preferably under vacuum, to a cooking temperature, usually 295F, although either a higher or lower temperature can be used. Heating is continued until the syrup has been reduced to a viscous mass of the desired water content. The concentrated sugar syrup is then transferred to a suitable blender or mixing slab. A uniform blend of alkaloid such as caffeine and anesthetic such as benzocaine is added, and blended thoroughly. A suitable blending temperature of the plastic mass is between about 240 and about 275F. Next is added the vitamin premix, and flavors and colors, as desired. The plastic mass can then be rolled and formed into discs, using ordinary hard candy compression machines, and allowed to harden at a reduced temperature, such as room temperature.
The following Examples, in the opinion of the inventor, represent preferred embodiments of the invention.
EXAMPLE 1 An active ingredient premix is prepared by mixing 630 grams of anhydrous caffeine, U.S.P. with 90 grams of benzocaine, N.F.
A vitamin blend is formed containing all essential vitamins for inclusion in the finished product.
The flavor is a wild cherry flavor, manufactured for use in high boiled confections.
The coloring to be used is FD and C Red, Number 40, which is used in a 10% solution for incorporation in high boiled confections.
A candy base is prepared by the mixing of ll5.7 pounds of 67% liquid sucrose and 51.7 pounds of high maltose corn syrup. This mixture is then heated to a temperature of 235 to 245 F in a precooker. After attaining the temperature, the mixture is pumped to the vacuum cooker where the temperature is raised to 250 to 270 F under 25 30 inches of vacuum.
This cooking removes water from the mass, so that the moisture level of the mass upon completion of cooking will be between 0.5 and 1%, and the total final weight of the mass will be about 1 19 pounds of sucrose and high maltose corn syrup solids.
The cooked mass is then placed in the premixer, where the premixed active ingredients are added. The first ingredient to be added is the caffeine and benzocaine premix. The next ingredients added are the vitamin premix, color, and flavor. After being mixed completely, the mass is transferred to the mixer cooling table. The mass is worked on this table automatically for a period of 4 to 6 minutes. During this period the mass will obtain a plastic consistency and the temperature will be lowered to between 170 and 190F. The mass is completely homogeneous.
The mass is then placed into forming equipment and run into discs or tablets that weigh three grams apiece. The discs or tablets are then placed on a cooling belt where the temperature is brought from 170F to 80- 90F in a period of 6 minutes. The finished candy product is then packaged for shipment.
EXAMPLE 2 The following is the formulation of a tablet, per tablet unit:
Amount Ingredient (mg) Caffeine 35 Benzocaine 5 Vitamin mixture l5 Flavoring 3O Dextrose, hydrous 2893 (compressible grade) Magnesium stearate 22 This mix can be compressed and tabletted using conventional tabletting equipment.
CLINICAL TEST Three hundred and eight obese subjects each at least pounds overweight were then separated into five paired groups, and subjected to a clinical test. Five paired groups of males and females were used in the test, each with a different regime.
Group I was assigned the amphetamine regime.
Group ll was assigned the AYDS regime.
Group II] was assigned the willpower regime, with a 35 bling, and cheating between meals, except for the product, and that they could use the product before meals or between meals whenever they had the desire to eat. They were further instructed to do no crash dieting, but merely to cut down on the sizes of their three meals. They were also allowed to drink alcoholic beverages.
A complete medical history was taken on each subject undertaking the regime. A general examination was made, including blood pressure determinations. The patients on each regime were weighed at the beginning of the regime, and at weekly intervals during the trial. The subjects were required to return once weekly to be weighed, to report the progress of the regime, and to report the presence or absence of side reactions.
Only subjects whose obesity was caused solely by improper eating habits were registered in the study. Patients with untreated glandular imbalance, endocrine conditions, disease, or other factors or reasons were excluded. To determine the cause of obesity in all cases,
each subject was carefully interviewed to ascertain all of his eating and drinking habits.
Each subject in the study was required to remain on the regime through a period of four weeks. The doubleblind procedure was employed for Groups IV and V, so
that the identity of the active appetite control product and the control product were unknown both to the patient and'to the doctor, and remained so until the conclusion of the trial. The control" product used was the product containing glucose and flavoring only. Supplies of all products were given to the patients on a weekly basis, to ensure their return to the clinic. Prescriptions for the amphetamines were issued weekly, as well.
Patients who failed to return for reexamination were considered dropouts. Those who advised in advance of their inability to return for reexamination for a valid reason were given an extra supply of the product, to
hold them until the next examination. Every effort was made to determine the reason or reasons why each subjected dropped out of the study. All followup data were recorded on case record forms, including reasons why the subject failed to cooperate and the reasons why they became dropouts.
The results of all five regimes are shown in Table i.
TABLE I.--RESULTS Group and regime No. of patients inducted into trial No. of patients who completed trial No. of patients who lost weight during entire triaL. No. of lbs. lost by patients who completed trial, lbs. No. of patients who lost Weight 1st week No. 01' lbs. lost 1st week, lbs Average weight loss 1st week, lbs. Minimum weight loss 1st week, 1bs Maximum weight loss 1st week, lbs Average weight loss during entire trial, lbs N0. of patients who gained Weight 1st week No. of lbs. gained 1st week, lbs No. 01' patients who remained at same weight 1st week Minimum weight loss during entire trial, lbs Maximum weight loss during entire trial, lbs, Average weekly weight loss during entire trial, lbs. N0. of patients who gained upon completion of trial No. of lbs. gained by patients who completed entire trial, lbs No. of patients who remained at same weight upon completion of entire trial No. of dropouts 1st week... No. of dropouts 2nd week No. 01 dropouts 3rd week. N o. of dropouts 4th week.
Total No. of dropouts I II III IV V Ampheta- O-T-C willpower mine proprietary (800-1, 200 Appetite (Dexedrine suppressant calorie control of 10 mg.) (AYBS) daily diet) Control invention Total 62 62 60 62 25 ll] U 32 24 16 9 27 206. G9. 25 40. 25 125. 00 31 36 41 199.50 80.00 06.75 111.50 4. 07 2.58 2. 6'.) 2. 72 0. 50 0. 50 0. 50 0. 25 13.00 6.00 6.25 7.75 8. 4. 33 l. 47 4. 63 1 11 3 (i 3. 25 14. 00 1. 50 16. 4 8 7 7 1. 25 1.00 0. 50 0.75 21.00 10.00 11.50 7.00 2.15 1.08 1.12 1.16 1 3 0 l 0. 50 3.00 (l (i. 50
0 0 (l 1 0 1 8 12 1-1 8 0 42 13 13 16 0 z 53 J 10 8 J 3 30 7 8 13 4 4 36 37 43 51 30 U Fifty-three patients out of a population of 62 on the Group V appetite control regime completed the trial, as compared with significantly fewer patients on the other regimes: Group I, amphetamines (25 of 62),
as compared with 79% of the patients in Group l, 5871 of those in Group III and 50% of Group II. It is to be further noted that 66% of the subjects in Group IV lost weight the first week, significantly more in number Group ll, OTC suppressant (19 of 62) and Group III th th e in Gr u s II or III willpo er 0f ignifican ly, Ore patients on The dropout population by the end of the trial for Group IV, control (32 of 62) completed the trial than Groups I to III was customarily high; amphetamines, those on any of the first three regimes. 60%; OTC suppressant, 69%; willpower, 85%. The
Subjects h Group V Q Completed the 9 dropout population for Group V is very low 14%). Sigmol'e that) twlee as fhueh Welght y the end the trial nificantly fewer patients in Group IV (48%) dropped as all sub ects combined who completed the trial on the f m h i l h those on any f h traditiemd first three regimes. Although both the Group IV and i S T bl N I Group V regimes offered oral gratification, neverthe- Th dropout population d i th fi d ond e those who eompleted the me] on Group V 10st v weeks of the trial also further demonstrates the ineffectimes more weight than those who completed the trial 15 tiveness f the regimes f Groups I to 1] h On Y P I mines, 34%; OTC suppressant, willpower, The number of h l Group v who lost welght Only two patients in Group V (3%) had dropped by the end ofthe trial (53) was more than double those by the end f the Second week The number who Q Group I on amphetamines (24) more than three dropped out of Group IV during this period was 27%, tlmes as y as those of P P H, on the OTC 20 again fewer than those on any of the first three regimes. Suppressant h nearly SIX as y as these The main reasons for patients dropping out were failf Group 011 PQ There Were nearly twlee ure to lose weight, side reactions, or dissatisfaction with as many who lost weight in Group V (53) as those in h regime to hi h h were i d Group IV (27). The presence or absence of side reactions is shown All 62 patients in Group V lost weight the first week, 25 i T bl N II,
TABLE H W Nugber of Tim as Rgportad 1nln'ita- Hyper Head 512- Dry Nervous Er Flam" Consfi' are m m use mmmswm wmww. 1% I Ampm- 5 a a 4 a a 7 14 '1 5 8 0 6 5 72 amine H OTC Propriell 888'- an? o o o 1 2 o o o o 0 0 1 2 14 1 O 21 m willpower o o o o o o 0 o o o 0 0 0 0 IV Control 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 2 v Appetite Controlol Invenfion 1 o 0 o 1 0 2 o 0' 0 o o 0 0 0 4 Side effects were most frequent and most severe, by far, among the amphetamine Group I. Tremor, nervousness, insomnia, nausea, constipation, palpitations, vertigo, drowsiness, dryness of the mouth and hyperactivity were fairly frequent reactions reported by those on the amphetamine regime. Several subjects on amphetamines denied side-effects in spite of overt evidence of their presence, or were reluctant to admit their occurrence for fear that the medication might be discontinued.
Constipation was a fairly frequent side effect, especially among subjects on the OTC suppressant Group ll regime; diarrhea, bloating, excessive gas, nausea and headache were also reported as side reactions caused by the OTC suppressant. Many subjects also complained that the suppressant (carmel candy) was uncomfortable in the mouth, causing dentures, caps and fillings to loosen or to fall out. Dryness of the mouth on occasion was reported by some subjects of Groups W and V. One subject said that the control product (hard candy) caused canker; one subject of Group V complained of insomnia, and one reported nausea.
At the conclusion of the 4 week test period, the weight reduction program for all Groups was continued for those patients who still were overweight. in this extended test. Group W was maintained to determine whether there would be a significant difference between the effectiveness of the appetitie control of the invention and the control. The results for all five Groups at the end of the 2 1 st week of the extended test are shown in Table lll.
Table Il Number of Patients on Protracted Study at End of 21st Week; Their Average Weekly Weight Loss; and Number of Patients Who Reduced to Normal Weight Table Il-Continued Number of Patients on Protracted Study at End of 21st Week; Their Average Weekly Weight Loss; and Number of Patients Who Reduced to Normal Weight Average Number of I Patient on Control- Regime Showed a net gain of 1.75 pounds.
The Table shows that the subjects of Group V on the appetite control composition of the invention lost significantly greater amounts of weight than those on any of the other four regimes, and they were continuing to lose an average of 2.2 lbs per week at the end of the fifth month of the test. Patients on the other four regimes during the protracted study continued to demonstrate unsatisfactory results, especially with regard to the number of dropouts.
The effect of the appetite control composition of the invention as an oral pacifier is considered to be a significant factor in aiding patients on this composition to lose more weight in larger numbers in less time than any of those on the other weight reduction regimes. In fact, a review of the literature over a 30 year period has shown that with the exception of Feinstein, Dole and Schwartz, The use of a formula diet for weight reduction of obese out-patients, Ann. Intern Med. 48 330-343, (1959), no author has published even a 20 lb weight loss in more than 29% of his patients. The percent of patients losing 40 lbs is far smaller. Thus, the results of this regime are quite remarkable, as compared to previously reported weight reduction regimes. in fact, the literature does not show a single successful long-term study using a diet regimen by itself or in combination with drugs, psychologic treatment, or exercise.
No patient on any of the four regimes except the appetite control regime of the invention successfully reduced to his normal weight during the 21 week study, despite the fact that each of the five regimes was equally divided as to the range of pounds overweight per patient. The average weekly weight loss of 2.2 lbs. by 43 patients on the appetite control composition of the invention is considered quite satisfactory, since this rate of loss allows for a gradual change in eating habits, and a gradual adjustment to an altered body image.
It has been found that weight loss decreases during protracted weight reduction programs. A considerable loss of body water (initial dehydration) is known to occur when obese patients start treatment with reducing diets. This may be due to changes in the diet which include reductions in the high intake of carbohydrates to a regime on which the patient depends in large measure on fat for much of his energy requirements. This mechanism might account for the decrease in the average weekly weight loss between the initial trial and the subsequent protracted study.
A weight maintenance program was also undertaken for test purposes with those patients participating who had attained their normal or desired weight, in order to ascertain whether this weight was maintained. Histories of maintenance of weight loss show even less success than histories of weight reduction (Fellows Am J M Sc 181 301-312, 1931 Mc Cann and Trulsonl Am DietetA 31 1108-1 110 (1955);Osserman and Dolger Ann Intern Med 34 72-79, (1951); Dole, Schwartz and Thaysen Am J Clin Nutr 2 381-390, (1954) The majority of patients regain all previous weight loss or even exceed previous weight losses. This is especially true of patients on amphetamines, and those attending diet clinics.
The patients on this weight maintenance program were quite similar in their histories. Prior to joining the clinical trial, they had been on and off diets for years, often under treatment with pharmacologic agents. None reported that they could maintain their weight loss, even though it was considerable in some cases, for any protracted period after reducing to their desired weight. All blamed their failures on traditional dieting methods, i.e., diets that prohibited eating and drinking most of the foods and beverages they desired or reducing by means of pharmacologic agents. Consequently, in the past, once their goal had been achieved, the impulse was to revert to indulging in foods and beverages, which their tastes demanded, in unrestricted amounts. They had not been adequately conditioned to do otherwise. Thorn and Bondy, (Obesity, in Principles of Internal Medicine, edited by Harrison TR, Adams, Bennett et a1, 5th ed. New York, McGraw-Hill Book Co., 1966, p 398 in evaluating the pharmacological treatment of obesity also have found that as soon as the pharmacologic effect wears off, or the medication is discontinued, appetite will return, and weight gain will recur, unless the patient 5 inherent capacity to control his food intake has been altered fundamentally.
A major requirement of the weight maintenance program was to test the effect that all desired foods and beverages had on individual metabolism. Patients began the program by ingesting small portions of whatever foods or beverages they wished, including desserts and alcoholic beverages. They recorded on a meal-bymeal, day-by-day basis the exact size of all portions of foods and beverages ingested. If, by the end of each week, they had not gained weight, they then knew the size of the portions they could eat or drink. If they had gained weight, they were advised to correspondingly reduce the amounts ingested. If they continued to lose weight, they were told to proportionately increase their portions. After a few weeks on the program while ingesting a wide variety of foods and beverages, they were able to adequately adjust, through habit, to the proper portions of both food and beverage without the need of calorie counting, which so many patients find difficult, inconvenient and impractical.
The entire population on the weight maintenance program (13 patients) had been on Group V, the appetite control regime. The subjects maintained their normal weight with the appetite control composition of the invention without fluctuating more than 1 or 2 pounds, plus or minus. When a pound or two was gained, they were trained to eliminate the gain the next week by adequate dieting.
Of great importance to these patients was the reeducation of eating customs which they had originally acquired while on the Group V appetite control regime. They had been instructed to ingest foods and beverages that they enjoyed, but in gradually reduced amounts each week. Consequently, when placed upon the weight maintenance program and permitted increased amounts of these pleasurable foods and beverages because no further weight losses were necessary, they felt rewarded; more importantly, they reported never being unduly hungry. The oral syndrome which previously resulted in snacking, nibbling and cheating was eliminated by the oral gratification provided by the appetite control composition of the invention.
Having regard to the foregoing disclosure, the following is claimed as the inventive and patentable embodiments thereof:
1. An appetite control composition for oral administration to a human subject to aid him in controlling his weight, comprising, in combination, a carbohydrate in an amount to obtain the effect ofcarbohydrate on hunger, and a nontoxic local anesthetic and an alkaloid stimulant in amounts to control the appetite.
2. An appetite control composition in accordance with claim 1, comprising at least one vitamin in an amount to supplement the vitamin intake of the user.
3. An appetite control composition in accordance with claim 1, in which the vitamins are selected from the group consisting of Vitamins A, B complex, C, D and E and mixtures thereof.
4. An appetite control composition in accordance with claim 1, in which the carbohydrate is selected from the group consisting of sucrose, glucose, maltose, fructose and dextrose and mixtures thereof.
5. An appetite control composition in accordance with claim 1, in which the carbohydrate is selected from the group consisting of corn syrup, cane sugar, and beet sugar.
6. An appetite control composition in accordance with claim 1 in which the nontoxic local anesthetic is a lower alkyl ester of para-amino benzoic acid lacking a secondary or tertiary amino group.
7. An appetite control composition in accordance with claim 6 in which the ester is selected from the group consisting of ethyl aminobenzoate, butyl aminobenzoate, butacaine sulfate, and orthoform.
8. An appetite control composition in accordance with claim 1, in which the alkaloid stimulant is caffeine or a caffeinerelated alkaloid.
9. An appetite control composition in accordance with claim 1, in the form of a candy or sweet.
10. An appetite control composition in accordance with claim 1, in the form of a solid.
11. An appetite control composition in accordance with claim 1, in the form of a liquid.
12. An appetite control composition in accordance with claim 1, comprising a flavoring agent to render the composition more palatable.
13. An appetite control composition in accordance with claim 1, comprising a coloring agent to render the composition more attractive.
14. An appetite control composition in accordance with claim 1, in a dosage unit form, in which the proportions of the essential ingredients are selected for an appetite control effect per dosage unit.
15. An appetite control composition in accordance with claim 14, in which the dosage unit form is within the range from about 1 to about l2 g. in weight.
16. An appetite control composition in accordance with claim 14, in which the amount of carbohydrate is sufficient to maintain blood sugar at a high normal level and is within the range from about 1000 to about 6000 mg. per unit dosage.
17. An appetite control composition in accordance with claim 15, in which the amount of anesthetic is within the range from about 3 to about 20 mg.
18. An appetite control composition in accordance with claim 14, in which the amount of alkaloid stimulant is within the range from about 10 to about mg.
19. An appetite control composition in accordance with claim 14, comprising at least one vitamin in an amount within the range from about 0.1 USRDA to about 5 USRDA.
20. An appetite control composition in accordance with claim 1, in which the amount of carbohydrate is within the range from about 1000 to about 6000 parts by weight.
21. An appetite control composition in accordance with claim 1, in which the amount of anesthetic is within the range from about 3 to about 20 parts by weight.
22. An appetite control composition in accordance with claim 1, in which the amount of alkaloid stimulant is within the range from about 10 to about 80 parts by weight.
23. An appetite control composition in accordance with claim 1, comprising at least one vitamin in an amount within the range from about 0.1 USRDA to about 5 USRDA.
24. An appetite control composition in accordance with claim 1, in a dosage unit form that is long-lasting in the mouth of the user.
25. An appetite control composition in accordance with claim 1, in which the carbohydrate is in the form of a solid matrix in which the other ingredients are dispersed.
26. A process for controlling weight of patients which comprises administering orally a composition in accordance with claim 1 and limiting the intake of foods by control of appetite therewith.
27. A process for controlling weight of'patients in accordance with claim 26, in which the appetite control composition is in dosage unit form.
28. A process for controlling weight of patients in accordance with claim 27, in which the dosage unit form is a candy or a sweet.
Claims (28)
1. AN APPETITE CONTROL COMPOSITION FOR ORAL ADMINISTRATION TO A HYMAN SUBJECT TO AID HIM IN CONTROLLING HIS WEIGHT, COMPRISING, IN COMBINATION, A CARBOHYDRATE IN AN AMOUNT TO OBTAIN THE EFFECT OF CARBOHYDRATE ON HUNGER, AND A NONTOXIC LOCAL ANESTHETIC AND AN ALKALOID STIMULTANT IN AMOUNTS TO CONTROL THE APPETITE.
2. An appetite control composition in accordance with claim 1, comprising at least one vitamin in an amount to supplement the vitamin intake of the user.
3. An appetite control composition in accordance with claim 1, in which the vitamins are selected from the group consisting of Vitamins A, B complex, C, D and E and mixtures thereof.
4. An appetite control composition in accordance with claim 1, in which the carbohydrate is selected from the group consisting of sucrose, glucose, maltose, fructose and dextrose and mixtures thereof.
5. An appetite control composition in accordance with claim 1, in which the carbohydrate is selected from the group consisting of corn syrup, cane sugar, and beet sugar.
6. An appetite control composition in accordance with claim 1 in which the nontoxic local anesthetic is a lower alkyl ester of para-amino benzoic acid lacking a secondary or tertiary amino group.
7. An appetite control composition in accordance with claim 6 in which the ester is selected from the group consisting of ethyl aminobenzoate, butyl aminobenzoate, butacaine sulfate, and orthoform.
8. An appetite control composition in accordance with claim 1, in which the alkaloid stimulant is caffeine or a caffeinerelated alkaloid.
9. An appetite control composition in accordance with claim 1, in the form of a candy or sweet.
10. An appetite control composition in accordance with claim 1, in the form of a solid.
11. An appetite control composition in accordance with claim 1, in the form of a liquid.
12. An appetite control composition in accordance with claim 1, comprising a flavoring agent to render the composition more palatable.
13. An appetite control composition in accordance with claim 1, comprising a coloring agent to render the composition more attractive.
14. An appetite control composition in accordance with claim 1, in a dosage unit form, in which the proportions of the essential ingredients are selected for an appetite control effect per dosage unit.
15. An appetite control composition in accordance with claim 14, in which the dosage unit form is within the range from about 1 to about 12 g. in weight.
16. An appetite control composition in accordance with claim 14, in which the amount of carbohydrate is sufficient to maintain blood sugar at a high normal level and is within the range from about 1000 to about 6000 mg. per unit dosage.
17. An appetite control composition in accordance with claim 15, in which the amount of anesthetic is within the range from about 3 to about 20 mg.
18. An appetite control composition in accordance with claim 14, in which the amount of alkaloid stimulant is within the range from about 10 to about 80 mg.
19. An appetite control composition in accordance with claim 14, comprising at least one vitamin in an amount within the range from about 0.1 USRDA to about 5 USRDA.
20. An appetite control composition in accordance with claim 1, in which the amount of carbohydrate is within the range from about 1000 to about 6000 parts by weight.
21. An appetite control composition in accordance with claim 1, in which the amount of anesthetic is within the range from about 3 to about 20 parts by weight.
22. An appetite control composition in accordance with claim 1, in which the amount of alkaloid stimulant is within the range from about 10 to about 80 parts by weight.
23. An appetite control composition in accordance with claim 1, comprising at least one vitamin in an amount within the range from about 0.1 USRDA to about 5 USRDA.
24. An appetite control composition in accordance with claim 1, in a dosage unit form that is long-lasting in the mouth of the user.
25. An appetite control composition in accordance with claim 1, in which the carbohydrate is in the form of a solid matrix in which the other ingredients are dispersed.
26. A procesS for controlling weight of patients which comprises administering orally a composition in accordance with claim 1 and limiting the intake of foods by control of appetite therewith.
27. A process for controlling weight of patients in accordance with claim 26, in which the appetite control composition is in dosage unit form.
28. A process for controlling weight of patients in accordance with claim 27, in which the dosage unit form is a candy or a sweet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00359056A US3856942A (en) | 1973-05-10 | 1973-05-10 | Appetite control composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00359056A US3856942A (en) | 1973-05-10 | 1973-05-10 | Appetite control composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US3856942A true US3856942A (en) | 1974-12-24 |
Family
ID=23412125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00359056A Expired - Lifetime US3856942A (en) | 1973-05-10 | 1973-05-10 | Appetite control composition |
Country Status (1)
Country | Link |
---|---|
US (1) | US3856942A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210637A (en) * | 1978-07-31 | 1980-07-01 | Massachusetts Institute Of Technology | Composition and method for suppressing appetite for calories as carbohydrates |
EP0306910A1 (en) * | 1987-09-11 | 1989-03-15 | Colgate-Palmolive Company | Appetite suppressant dentifrice |
WO1989012447A1 (en) * | 1988-06-16 | 1989-12-28 | Neurex Corporation | Benzothiophene derivatives useful for modifying feeding behavior and obsessive-compulsive behavior |
US5508282A (en) * | 1993-05-17 | 1996-04-16 | Jeffrey Tulin-Silver | Composition and method for treating acute or chronic rhinosinusitis |
US20040018990A1 (en) * | 2002-07-25 | 2004-01-29 | Harvey Rosner | Treatment of obesity |
US20040191918A1 (en) * | 2003-03-28 | 2004-09-30 | Sandrine Isz | Evaluation of bitterness of active drugs |
US20050136112A1 (en) * | 2003-12-19 | 2005-06-23 | Pediamed Pharmaceuticals, Inc. | Oral medicament delivery system |
US20050171003A1 (en) * | 1999-11-03 | 2005-08-04 | Kjell Malmlof | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
US20060286181A1 (en) * | 2005-06-17 | 2006-12-21 | Gardiner Paul T | Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism |
US20100124578A1 (en) * | 2008-11-17 | 2010-05-20 | Heuer Marvin A | Appetite-suppressing weight management composition |
US20110117175A1 (en) * | 2009-11-18 | 2011-05-19 | Rosenbaum Richard J | Sweet analgesic for use in medical procedures or treatments |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9314048B2 (en) | 2007-03-14 | 2016-04-19 | The Concentrate Manufacturing Company Of Ireland | Beverage products with non-nutritive sweetener and bitterant |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2714083A (en) * | 1951-08-07 | 1955-07-26 | Jr Edgar A Ferguson | Appetite satient |
US2935447A (en) * | 1957-02-19 | 1960-05-03 | Kelco Co | Appetite depressant containing alginate |
US2952548A (en) * | 1956-10-05 | 1960-09-13 | Lincoln T Work | Protopectin composition and method of preparation |
US3143463A (en) * | 1959-12-21 | 1964-08-04 | Lundbeck & Co As H | 1-(para-halophenyl)-2-loweralkyl-amino propane: weight reducing composition and method |
-
1973
- 1973-05-10 US US00359056A patent/US3856942A/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2714083A (en) * | 1951-08-07 | 1955-07-26 | Jr Edgar A Ferguson | Appetite satient |
US2952548A (en) * | 1956-10-05 | 1960-09-13 | Lincoln T Work | Protopectin composition and method of preparation |
US2935447A (en) * | 1957-02-19 | 1960-05-03 | Kelco Co | Appetite depressant containing alginate |
US3143463A (en) * | 1959-12-21 | 1964-08-04 | Lundbeck & Co As H | 1-(para-halophenyl)-2-loweralkyl-amino propane: weight reducing composition and method |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210637A (en) * | 1978-07-31 | 1980-07-01 | Massachusetts Institute Of Technology | Composition and method for suppressing appetite for calories as carbohydrates |
EP0306910A1 (en) * | 1987-09-11 | 1989-03-15 | Colgate-Palmolive Company | Appetite suppressant dentifrice |
AU616198B2 (en) * | 1987-09-11 | 1991-10-24 | Colgate-Palmolive Company, The | Appetite suppressant dentifrice |
WO1989012447A1 (en) * | 1988-06-16 | 1989-12-28 | Neurex Corporation | Benzothiophene derivatives useful for modifying feeding behavior and obsessive-compulsive behavior |
US5508282A (en) * | 1993-05-17 | 1996-04-16 | Jeffrey Tulin-Silver | Composition and method for treating acute or chronic rhinosinusitis |
US20050171003A1 (en) * | 1999-11-03 | 2005-08-04 | Kjell Malmlof | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
US20040018990A1 (en) * | 2002-07-25 | 2004-01-29 | Harvey Rosner | Treatment of obesity |
US20040191918A1 (en) * | 2003-03-28 | 2004-09-30 | Sandrine Isz | Evaluation of bitterness of active drugs |
US20050136112A1 (en) * | 2003-12-19 | 2005-06-23 | Pediamed Pharmaceuticals, Inc. | Oral medicament delivery system |
US20060286181A1 (en) * | 2005-06-17 | 2006-12-21 | Gardiner Paul T | Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism |
US9314048B2 (en) | 2007-03-14 | 2016-04-19 | The Concentrate Manufacturing Company Of Ireland | Beverage products with non-nutritive sweetener and bitterant |
US20100124578A1 (en) * | 2008-11-17 | 2010-05-20 | Heuer Marvin A | Appetite-suppressing weight management composition |
US20110117175A1 (en) * | 2009-11-18 | 2011-05-19 | Rosenbaum Richard J | Sweet analgesic for use in medical procedures or treatments |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3856942A (en) | Appetite control composition | |
US6159505A (en) | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine | |
US9387168B2 (en) | Chewing gum with tomatidine | |
US6197329B1 (en) | Anti-nausea compositions and methods | |
US6224873B1 (en) | Regulation of appetite, body weight and athletic function with materials derived from citrus varieties | |
US20040037788A1 (en) | Functional gums, lozenges and lollipops | |
US20040005368A1 (en) | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite | |
US6340482B1 (en) | Methods for inducing weight loss in a human with materials derived from Citrus varieties | |
EP0885008B1 (en) | The regulation of body weight with materials derived from citrus varieties | |
USRE38566E1 (en) | Therapeutic carbohydrate blends for treating and aiding premenstrual syndrome | |
WO2007042745A1 (en) | Chocolate based appetite suppressant | |
US7550161B2 (en) | Nutritional weight loss agent and method | |
US20010043956A1 (en) | Hangover cure | |
US7094762B2 (en) | Use of ribose to treat fibromyalgia | |
US6793935B2 (en) | Mineral supplement | |
McKENZIE et al. | Serum theophylline levels in asthmatic children after oral administration of two slow-release theophylline preparations. | |
US20070259094A1 (en) | N-acetylglucosamine as a food and beverage additive | |
US4539315A (en) | Sublingually absorbable nontoxic aspirin composition | |
US20020122815A1 (en) | Compositions and methods of carbohydrate dosing | |
US4273794A (en) | Composition containing honey | |
US6316499B1 (en) | Methods for increasing the muscle mass of a human with materials derived from citrus varieties | |
US9253991B2 (en) | Chewing gum with B vitamins | |
US20040071855A1 (en) | Glucosamine as a food and beverage additive | |
CA2325033C (en) | Use of ribose to treat fibromyalgia | |
US20180055849A1 (en) | Nutraceutical capsule and tablet formulations providing enhanced mental clarity, concentration and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal |